ALK阳性-话题@MedSci

#ALK阳性#

68篇内容 | 2266人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1987551, encodeId=83e2198e5515f, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=肺癌新一代靶向药劳拉替尼：显着改善ALK阳性NSCLC患者的无进展生存期, objectType=article, longId=198887, objectId=e4c319888efe, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e4c319888efe, replyNumber=0, likeNumber=80, createdTime=2020-10-23, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e4c319888efe, moduleTitle=肺癌新一代靶向药劳拉替尼：显着改善ALK阳性NSCLC患者的无进展生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e4c319888efe)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987546, encodeId=5c61198e546ff, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=ALUNBRIG（brigatinib）治疗ALK阳性NSCLC的中长期数据：两年随访展现的优势, objectType=article, longId=183563, objectId=716c183563f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=716c183563f0, replyNumber=0, likeNumber=85, createdTime=2020-09-29, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=716c183563f0, moduleTitle=ALUNBRIG（brigatinib）治疗ALK阳性NSCLC的中长期数据：两年随访展现的优势, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=716c183563f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987550, encodeId=ad02198e55010, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=FDA批准武田的酪氨酸激酶抑制剂ALUNBRIG（brigatinib），一线治疗ALK阳性的转移性非小细胞肺癌患者, objectType=article, longId=194626, objectId=133519462630, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=133519462630, replyNumber=0, likeNumber=88, createdTime=2021-02-22, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=133519462630, moduleTitle=FDA批准武田的酪氨酸激酶抑制剂ALUNBRIG（brigatinib），一线治疗ALK阳性的转移性非小细胞肺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=133519462630)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987548, encodeId=22bb198e54892, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=Sci Rep：ALK阳性非小细胞肺癌中双重抑制ALK和MEK抑制细胞生长的机制, objectType=article, longId=184991, objectId=d09c18499171, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d09c18499171, replyNumber=0, likeNumber=77, createdTime=2020-10-16, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d09c18499171, moduleTitle=Sci Rep：ALK阳性非小细胞肺癌中双重抑制ALK和MEK抑制细胞生长的机制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d09c18499171)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987542, encodeId=d8b7198e5420c, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=于壮教授：精准治疗“慢病”管理ALK阳性非小细胞肺癌, objectType=article, longId=175747, objectId=f5121e574786, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f5121e574786, replyNumber=0, likeNumber=89, createdTime=2019-12-01, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f5121e574786, moduleTitle=于壮教授：精准治疗“慢病”管理ALK阳性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f5121e574786)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987547, encodeId=55fb198e5472f, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=ALK阳性NSCLC的治疗如何权衡PFS和OS？, objectType=article, longId=184371, objectId=c0ab1843e149, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c0ab1843e149, replyNumber=0, likeNumber=57, createdTime=2020-06-23, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c0ab1843e149, moduleTitle=ALK阳性NSCLC的治疗如何权衡PFS和OS？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c0ab1843e149)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987544, encodeId=488f198e54436, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=吴一龙教授：ASCEND-7研究惊艳ESMO，塞瑞替尼为ALK阳性有症状脑转移和脑膜转移NSCLC患者带来获益, objectType=article, longId=181755, objectId=c3af181e55db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c3af181e55db, replyNumber=0, likeNumber=65, createdTime=2020-04-03, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c3af181e55db, moduleTitle=吴一龙教授：ASCEND-7研究惊艳ESMO，塞瑞替尼为ALK阳性有症状脑转移和脑膜转移NSCLC患者带来获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c3af181e55db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987543, encodeId=62b8198e543a6, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=刘基巍教授：精准时代下ALK阳性NSCLC的治疗新选择, objectType=article, longId=176019, objectId=2bce1e60194b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2bce1e60194b, replyNumber=0, likeNumber=64, createdTime=2020-02-10, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2bce1e60194b, moduleTitle=刘基巍教授：精准时代下ALK阳性NSCLC的治疗新选择, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2bce1e60194b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987545, encodeId=e655198e545d8, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=恩沙替尼治疗ALK阳性晚期非小细胞肺癌患者, objectType=article, longId=182449, objectId=a87318244947, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a87318244947, replyNumber=0, likeNumber=78, createdTime=2020-07-04, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a87318244947, moduleTitle=恩沙替尼治疗ALK阳性晚期非小细胞肺癌患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a87318244947)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987536, encodeId=86be198e5363c, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=NEJM：布吉他滨一线治疗ALK阳性晚期非小细胞肺癌的疗效优于克唑替尼, objectType=article, longId=149668, objectId=a218149668eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a218149668eb, replyNumber=0, likeNumber=50, createdTime=2019-04-15, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a218149668eb, moduleTitle=NEJM：布吉他滨一线治疗ALK阳性晚期非小细胞肺癌的疗效优于克唑替尼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a218149668eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987539, encodeId=de9c198e5391b, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=ANN ONCOL：ALK FISH阳性率与ALK阳性非小细胞肺癌患者接受克唑替尼治疗有效性之间的关系, objectType=article, longId=150025, objectId=d10815002592, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d10815002592, replyNumber=0, likeNumber=63, createdTime=2019-01-04, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d10815002592, moduleTitle=ANN ONCOL：ALK FISH阳性率与ALK阳性非小细胞肺癌患者接受克唑替尼治疗有效性之间的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d10815002592)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987541, encodeId=38f0198e541ec, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=ALK阳性肺癌全新III期临床研究成果, objectType=article, longId=154858, objectId=84b91548588d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=84b91548588d, replyNumber=0, likeNumber=68, createdTime=2018-12-31, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=84b91548588d, moduleTitle=ALK阳性肺癌全新III期临床研究成果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=84b91548588d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987538, encodeId=9a01198e5381d, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=2018年WCLC：Brigatinib为ALK阳性非小细胞肺癌患者提供更好的反应率, objectType=article, longId=149829, objectId=2dc21498290c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2dc21498290c, replyNumber=0, likeNumber=75, createdTime=2019-04-19, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2dc21498290c, moduleTitle=2018年WCLC：Brigatinib为ALK阳性非小细胞肺癌患者提供更好的反应率, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2dc21498290c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987533, encodeId=0876198e533d0, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=CLIN CANCER RES：Ensartinib（X-396）治疗ALK阳性非小细胞肺癌, objectType=article, longId=141979, objectId=3d0a1419e91d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d0a1419e91d, replyNumber=0, likeNumber=69, createdTime=2018-11-26, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d0a1419e91d, moduleTitle=CLIN CANCER RES：Ensartinib（X-396）治疗ALK阳性非小细胞肺癌, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d0a1419e91d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987531, encodeId=9454198e53136, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=Lancet Oncol：EGFR/ALK阳性的NSCLC多线靶向治疗后仍可用免疫治疗？, objectType=article, longId=132965, objectId=c7691329653a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c7691329653a, replyNumber=0, likeNumber=73, createdTime=2018-12-11, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c7691329653a, moduleTitle=Lancet Oncol：EGFR/ALK阳性的NSCLC多线靶向治疗后仍可用免疫治疗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c7691329653a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987540, encodeId=b44e198e54023, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=ALK阳性非小细胞肺癌病例分享, objectType=article, longId=151632, objectId=3d4415163229, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d4415163229, replyNumber=0, likeNumber=82, createdTime=2018-11-02, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d4415163229, moduleTitle=ALK阳性非小细胞肺癌病例分享, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d4415163229)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987530, encodeId=d441198e53039, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=JCO：EML4-ALK变体亚型是否影响ALK阳性患者的疗效和结局？, objectType=article, longId=128502, objectId=4171128502ae, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4171128502ae, replyNumber=0, likeNumber=73, createdTime=2018-10-09, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4171128502ae, moduleTitle=JCO：EML4-ALK变体亚型是否影响ALK阳性患者的疗效和结局？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4171128502ae)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987532, encodeId=9206198e532bd, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=JCO：不幸中的万幸 —— ALK阳性脑转移NSCLC患者耐药后的新选择：Brigatinib, objectType=article, longId=139302, objectId=203d1393022a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=203d1393022a, replyNumber=0, likeNumber=59, createdTime=2018-06-01, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=203d1393022a, moduleTitle=JCO：不幸中的万幸 —— ALK阳性脑转移NSCLC患者耐药后的新选择：Brigatinib, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=203d1393022a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987535, encodeId=6c75198e53525, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=Takeda的Alunbrig在ALK阳性NSCLC的PFS击败了辉瑞公司的Xalkori, objectType=article, longId=145287, objectId=5cfb14528e84, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5cfb14528e84, replyNumber=0, likeNumber=60, createdTime=2018-11-08, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5cfb14528e84, moduleTitle=Takeda的Alunbrig在ALK阳性NSCLC的PFS击败了辉瑞公司的Xalkori, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5cfb14528e84)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1987537, encodeId=3af2198e5376a, content=<a href='/topic/show?id=540623233e' target=_blank style='color:#2F92EE;'>#ALK阳性#</a>, objectTitle=【2018 CSCO】ALK阳性非小细胞肺癌治疗，如何排兵布阵？, objectType=article, longId=149690, objectId=914b14969087, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=914b14969087, replyNumber=0, likeNumber=73, createdTime=2018-12-04, rootId=0, userName=xjy02, userId=d59291, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=914b14969087, moduleTitle=【2018 CSCO】ALK阳性非小细胞肺癌治疗，如何排兵布阵？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=914b14969087)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ALK阳性

2020-05-29

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

肺癌新一代靶向药劳拉替尼：显着改善ALK阳性NSCLC患者的无进展生存期

2020-10-23

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

ALUNBRIG（brigatinib）治疗ALK阳性NSCLC的中长期数据：两年随访展现的优势

2020-09-29

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

FDA批准武田的酪氨酸激酶抑制剂ALUNBRIG（brigatinib），一线治疗ALK阳性的转移性非小细胞肺癌患者

2021-02-22

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

Sci Rep：ALK阳性非小细胞肺癌中双重抑制ALK和MEK抑制细胞生长的机制

2020-10-16

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

于壮教授：精准治疗“慢病”管理ALK阳性非小细胞肺癌

2019-12-01

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

ALK阳性NSCLC的治疗如何权衡PFS和OS？

2020-06-23

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

吴一龙教授：ASCEND-7研究惊艳ESMO，塞瑞替尼为ALK阳性有症状脑转移和脑膜转移NSCLC患者带来获益

2020-04-03

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

刘基巍教授：精准时代下ALK阳性NSCLC的治疗新选择

2020-02-10

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

恩沙替尼治疗ALK阳性晚期非小细胞肺癌患者

2020-07-04

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

NEJM：布吉他滨一线治疗ALK阳性晚期非小细胞肺癌的疗效优于克唑替尼

2019-04-15

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

ANN ONCOL：ALK FISH阳性率与ALK阳性非小细胞肺癌患者接受克唑替尼治疗有效性之间的关系

2019-01-04

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

ALK阳性肺癌全新III期临床研究成果

2018-12-31

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

2018年WCLC：Brigatinib为ALK阳性非小细胞肺癌患者提供更好的反应率

2019-04-19

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

CLIN CANCER RES：Ensartinib（X-396）治疗ALK阳性非小细胞肺癌

2018-11-26

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

Lancet Oncol：EGFR/ALK阳性的NSCLC多线靶向治疗后仍可用免疫治疗？

2018-12-11

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

ALK阳性非小细胞肺癌病例分享

2018-11-02

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

JCO：EML4-ALK变体亚型是否影响ALK阳性患者的疗效和结局？

2018-10-09

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

JCO：不幸中的万幸 —— ALK阳性脑转移NSCLC患者耐药后的新选择：Brigatinib

2018-06-01

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

Takeda的Alunbrig在ALK阳性NSCLC的PFS击败了辉瑞公司的Xalkori

2018-11-08

xjy02 (审核中...)

前往app查看评论内容

#ALK阳性#

【2018 CSCO】ALK阳性非小细胞肺癌治疗，如何排兵布阵？

2018-12-04

科室
- - 订阅+
  - 更多科室
工具
服务